Digestive system

Abstract

Stereotactic body radiotherapy for gastrointestinal targets has primarily been employed in the liver and pancreas. In these and other gastrointestinal organs, dose limiting toxicity remains the primary impediment to treatment, but advances in targeting and tracking precision have improved outcomes over recent years. Greater advances may be achieved in the coming years through the combination of stereotactic body radiotherapy with systemic chemotherapy or targeted molecular agents.